Silicon Laboratories Inc. (SLAB) Q2 2025 Earnings Call Transcript

Silicon Labs (SLAB) reported strong Q2 2025 results, with revenue of $193 million, up 33% year-over-year, and non-GAAP EPS of $0.11, exceeding guidance. The company attributed growth to successful conversion of its design win pipeline, with 10 of 12 major customer ramps on track or ahead for 2025, driving double-digit year-over-year increases in both Home & Life and Industrial & Commercial segments. Key drivers included the Series 2 platform, new Wi-Fi applications like the Roku battery camera, and expanding healthcare initiatives, with continuous glucose monitoring still targeted to reach 10% of revenue. SLAB also announced volume shipments of its first Series 3 device, the 301, achieving PSA Level 4 security certification. For Q3 2025, SLAB projects revenue of $200-$210 million and non-GAAP EPS of $0.20-$0.40, expecting to outperform the broader semiconductor market this year despite tariff uncertainties, as customer inventories remain low.

Analysis

Silicon Laboratories (SLAB) delivered strong Q2 2025 results, with revenue of $193 million, up 33% year-over-year and in line with guidance, and non-GAAP EPS of $0.11, beating the midpoint forecast. The growth is primarily driven by the successful execution of its design win pipeline, with management confirming that 10 of its 12 largest customer ramps are on track or ahead of schedule for 2025. Both business segments demonstrated robust year-over-year growth; Industrial and Commercial revenue grew 25% to $110 million, fueled by electronic shelf labels and smart metering, while Home & Life revenue increased 45% to $83 million, largely due to new medical customer ramps more than doubling. The company's Series 2 platform continues to secure market share, evidenced by a significant design win with Roku for a battery-powered camera. Looking forward, SLAB is introducing its Series 3 platform, with the 301 device now shipping with industry-first PSA Level 4 security certification, signaling a continued focus on innovation. Financially, the company shows strong operational discipline, with non-GAAP gross margin improving 90 basis points to 56.3% and guided to expand further to 57%-58% in Q3. The outlook for Q3 is positive, with revenue projected at $200-$210 million, implying 23% year-over-year growth, and management expresses confidence in outperforming the broader semiconductor market this year. Notably, channel inventory remains low at 51 days against a target of 70-75, and customer surveys indicate a reduction in end-customer inventory, mitigating concerns of demand pull-forward despite tariff uncertainties.

Key Decisions for Investors

• Investors should focus on the company's clear execution on its substantial design win pipeline, which management identifies as the primary driver for its strong growth and its confidence in outperforming the broader market this year.
• Monitor the non-GAAP gross margin expansion, guided to 57%-58% for Q3, as the favorable mix from industrial customers and disciplined expense control creates a clear path for significant operating leverage and accelerated earnings.
• Consider the long-term growth vectors from the new Series 3 platform and strategic initiatives in markets like connected healthcare, where the continuous glucose monitoring opportunity is still targeted to reach 10% of total revenue.
• While management downplays the risk, investors should remain watchful of channel inventory levels and any potential demand shifts related to tariff discussions, as lead times have become more turns-based, limiting long-term visibility.